BridgeBio Oncology Therapeutics BBOT
BridgeBio Oncology Therapeutics reports $34.18 million net loss
BridgeBio Oncology Therapeutics (BBOT) filed a 10-Q with the SEC on Nov 10, 2026, 4:21 pm ET. Source: the filing on SEC EDGAR.
Quarterly report, 9 new risk factors
- Form
- 10-Q
- Filed
- Importance
- Notable
- Accession
- 0001193125-26-455521
- Net loss: $34.18 million for the three months ended Sep 30, 2026
- Diluted EPS: -$0.43 for the three months ended Sep 30, 2026
- Cash and equivalents: $76.48 million at Sep 30, 2026
Written from the 10-Q on EDGAR. AI can make mistakes. Check the filing.
What changed since last quarter
9 new risk factors · 4 removed
Compared with the 10-Q for the period ended Jun 30, 2026.
| This filing | Previous | Change vs prior 10-Q | |
|---|---|---|---|
| Operating income and margin | −$37.49M | −$60.19M | +38% |
| Net income | −$34.18M | −$56.45M | +40% |
| Operating cash flow | −$28.37M | −$44.36M | +36% |
| Cash | $76.48M | $54.06M | +42% |
New risk factors (9)
- • timely receipt of marketing approvals from applicable regulatory authorities for any product candidates for which we successfully complete clinical development and for any third-party product candidates for which our product candidates are designed to serve as a second-line therapy in the applicable patient…
- • in the case of BBO-8520 as a potential second-line therapy for NSCLC patients whose disease progresses following treatment with a KRASG12C inhibitor, the timely receipt by third parties of marketing approvals from applicable regulatory authorities for, and the successful commercialization of, KRASG12C inhibitors…
- We are also unable to predict how changing regulatory requirements, global economic conditions or ongoing geopolitical conflicts, trade policy, and related global economic sanctions, or potential global health concerns will affect our third-party suppliers and manufacturers. Any negative impact of such matters on our…
- • unfavorable publicity relating to our product candidates or similar approved products or product candidates of third parties; and
- While we implement IT controls to reduce the risk of a security incident or data breach, there is no guarantee that these measures will be adequate to safeguard all systems.
- and 4 more in the filing
Removed risk factors (4)
- • timely receipt of marketing approvals from applicable regulatory authorities for any product candidates for which we successfully complete clinical development;
- We are also unable to predict how changing regulatory requirements, global economic conditions or ongoing geopolitical conflicts, trade policy, and related global economic sanctions, or potential global health concerns will affect our third-party suppliers and manufacturers. Any negative impact of such matters on our…
- Like other companies in the industry, we, and our third party vendors, have experienced threats and security incidents relating to their information technology systems and infrastructure. To the extent that any disruption, security incident, or data breach were to result in a loss, destruction, unavailability…
- For example, in April 2025, the United States imposed "reciprocal" tariffs, which were broad tariffs on imports from virtually all countries, with particularly high tariffs on imports from China. The U.S. Supreme Court invalidated the reciprocal tariffs on February 20, 2026; however, the current administration has…